Clinical Trial Detail

NCT ID NCT03873493
Title A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications

prolymphocytic leukemia

Therapies

Ibrutinib + Venetoclax

Age Groups: senior adult

No variant requirements are available.